II. Indications

  1. ABC Hemorrhage Score of 2 or more OR
  2. Hemorrhagic Shock with 2 or more risk factors as below (see Houston protocol below) OR
  3. Trauma with Hemorrhage requiring Transfusion of Packed Red Blood Cells that replace >50% of Blood Volume
    1. More than 50% of Blood Volume in 4 hours (4-6 units replaced in an average adult)
    2. More than 100% of Blood Volume in 24 hours (8-12 units replaced in an average adult)
  4. Calculating total Blood Volume in units
    1. Blood Volume is 70 ml/kg in adults, 80 ml/kg in children, 100 ml/kg in infants
    2. One unit or pint of blood is 450 ml
    3. Blood Volume in Units = wtKg/6.4 in adults, wtKg/5.6 in children, wtKg/4.5 in neonates
  5. Critical Administration Threshold (CAT)
    1. Three or more units pRBC transfused within 60 minutes
    2. CAT+1: 3 units in 1 hour
    3. CAT+2: A second set of 3 units pRBC transfused in 1 hour
    4. CAT+3: A third set of 3 units pRBC transfused in 1 hour
    5. CAT+4: A fourth set of 3 units pRBC transfused in 1 hour
    6. Savage (2015) J Trauma Acute Care Surg 78(2):224-9 +PMID: 25757105 [PubMed]

III. Risk Factors: Predictors of Massive Blood Transfusion (MBT)

  1. Emergency department arrival Heart Rate >120
  2. Emergency department arrival Heart Rate <90 mmHg
  3. Positive FAST Exam
  4. Penetrating Trauma
  5. Uncrossed match blood use in the Emergency Department

IV. Diagnosis: Triggers for Massive Blood Transfusion (MBT)

  1. Assessment of Blood Consumption Score
    1. Score >=2 predicts MBT in 40% of cases (100% if score of 4)
  2. Houston Protocol
    1. Two or more criteria suggest need for Massive Blood Transfusion
    2. Test Sensitivity: 86%
    3. PPV: 53%
    4. NPV: 96%
  3. Revised Assessment of Bleeding and Transfusion Score (RABT Score)
    1. Criteria
      1. Penetrating Injury
      2. Positive FAST
      3. Shock Index >1.0
      4. Pelvic Fracture
    2. Interpretation
      1. Total score >=2 predicts need for Massive Transfusion

V. Mechanism

  1. Dilutional Coagulopathy
    1. Coagulopathy develops with Massive Blood Transfusion (dilution of Coagulation Factors)
  2. FFP helps treat the Coagulopathy by replacing Fibrinogen, C1 esterase, antiplasmins and other factors
  3. Thromboelastography (TEG or r-TEG)
    1. Measures overall coagulation efficiency and can identify the severity of coagulation defects
    2. Typically limited to large Trauma Centers

VI. Protocol: Primary 1:1:1 replacement

  1. Notify the blood bank early regarding need for Massive Transfusion Protocol
  2. Red Blood Cell replacement remain the first priority
    1. Continue Blood Transfusion until bleeding is controlled or patient becomes hemodynamically stable
  3. Ratio of 1:1:1 of Platelets : plasma : Red Blood Cells is preferred (decreased mortality compared with 1:1:2)
    1. Replace 1 unit of Fresh Frozen Plasma for every 1 unit of Packed Red Blood Cells (pRBC)
      1. Typically the limiting factor (insufficient supply)
      2. Available in some centers as Jumbo Plasma (2 to 3 plasma units at 450 to 600 ml)
      3. Ideal universal donor is AB Plasma, which is in short supply
      4. Aim for balanced transfusion within 3 hours of start
    2. Replace 1 unit of apheresis Platelets for every 6-8 units of Packed Red Blood Cells
      1. Each unit of apheresis Platelets is equivalent to prior Platelet 6-pack
      2. Empiric Platelet Transfusion based on balanced ratio may result in worse outcomes
        1. Consider Platelet Transfusion when Platelet Count <50,000 (or 100,000 if Intracerebral Hemorrhage)
  4. Whole Blood Transfusion
    1. Universal donor Whole Blood Transfusion is FDA approved in Trauma and replaces 1:1:1 individual components
    2. Some major Trauma Centers stock universal donor whole blood for Massive Hemorrhage cases
    3. Associated with improved survival in severe Traumatic Hemorrhage
    4. References
      1. McCollum and Knight in Swadron (2022) EM:Rap 22(12): 8-9
      2. Shea (2020) Transfusion 60(suppl 3): S2-9 +PMID:32478896 [PubMed]

VII. Protocol: Other Measures

  1. Consider Cryoprecipitate (or Fibrinogen Concentrate)
    1. Cryoprecipitate primarily replaces Fibrinogen (but also Von Willebrand Factor, Factor VIII)
      1. Fibrinogen is also contained in FFP, which is the primary replacement unit in Massive Blood Transfusion
      2. Fibrinogen may also be given instead of Cryoprecipitate (and is preferred when available)
    2. Obtain Fibrinogen and r-TEG Level after 12 units pRBC, or bleeding despite 1:1:1 replacement
    3. Cryoprecipitate or Fibrinogen indications
      1. Fibrinogen level <150 - 180 mg/dl OR
      2. r-TEG Alpha angle shallow (e.g. <50 to 66 degrees)
    4. Cryoprecipitate dosing
      1. Typical adult dose 10 units
      2. One unit Cryoprecipitate per 5 kg wtKg raises Fibrinogen 100 mg/dl
    5. Fibrinogen Concentrate dosing
      1. Dose: 4 grams
      2. Preferred over Cryoprecipitate as raises Fibrinogen more predictably
      3. Consider empiric Fibrinogen administration (typically low at early stages of Hemorrhage)
  2. Consider Prothrombin Complex Concentrate (PCC) 1-2 doses
    1. Do not use beyond 6-7 hours from bleeding onset (due to increased bleeding risk)
    2. Consider if bleeding is refractory to multiple units with 1:1:1 replacement
  3. Consider Tranexamic Acid
    1. Also consider in r-TEG LY30 >3%
    2. Give within first 3 hours of injury
      1. Avoid if more than 3 hours after injury (no benefit, and possible harm)
  4. Consider Calcium Supplementation
    1. Blood chelators (e.g. citrate) lower Serum Calcium and may alter hemodynamics
    2. Give 1 g Calcium Chloride (or 2 to 3 g Calcium Gluconate) at start of Massive Transfusion Protocol (or after third unit)
    3. Give 1 g Calcium Chloride (or 2 to 3 g Calcium Gluconate) for every 3 to 6 units of transfused blood
    4. Weingart and Swaminathan in Swadron (2022) EM:Rap 22(7): 2-3

VIII. Precautions

  1. Avoid Hypothermia (worsens Coagulopathy when <35 C, and especially when <32 C)
    1. Keep Body Temperature >35 C
    2. Warm blood (each unit may lower Body Temperature 0.25 C)
    3. Consider Bair Hugger
  2. Avoid excessive crystalloid (NS, LR)
  3. Prevent acidosis

IX. Complications

X. References

  1. Orman and DeLoughery in Herbert (2017) EM:Rap 17(4): 5-6
  2. Freeman and Bourland (2021) Crit Dec Emerg Med 35(12): 3-11
  3. Petrosoniak and Swaminathan (2022) EM:Rap 22(11): 5-7
  4. Holcomb (2012) Arch Surg 15:1-10 [PubMed]
  5. Holcomb (2015) JAMA 313(5): 471-82 +PMID:25647203 [PubMed]

Images: Related links to external sites (from Bing)

Related Studies